CellaVision has through its wholly owned subsidiary CellaVision Inc.,
performed a strategic acquisition by acquiring the assets and
intellectual property of Triangle Imaging Inc. (TII) from Triangle
Biomedical Sciences Inc. (TBS). TII, formerly known as IMI, Intelligent
Medical Imaging Inc., has until now been CellaVision's leading
competitor in the digital analysis of white blood cells. TII is based in
Jupiter, Florida where CellaVision Inc. will now have its base.

CellaVision will now have direct access to the automated microscope
MICRO21, including technology, inventory, existing customers and also a
detailed market analysis of potential customers in the U.S. market. The
new CellaVision team will provide direct and immediate access to the
American market and also bring their substantial experience and
knowledge.

"Through the acquisition, we will gain much quicker access to the U.S.
market for our...